MedTrace Logo

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection

NCT06331455 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-07-22

No results posted yet for this study

Summary

The SUPER trial is a prospective Phase II trial. It is designed for patients with stage 2 or 3 non-small cell lung cancer (NSCLC) prior to surgery.

Patients who are enrolled in this trial will receive combination of Non-ablative oligofractionated radiation (NORT) and two cycles of Durvalumab, an immunotherapy drug before their surgery.

Conditions

  • Lung Cancer Patients
  • Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Durvalumab

Two doses of durvalumab (1500 mg IV)

RADIATION

Non-ablative oligofractionated radiation (NORT)

12 Gy of Radiation in 3 fractions

Sponsors & Collaborators

  • Ozmosis Research Inc.

    collaborator INDUSTRY

  • Marc de Perrot

    lead OTHER

Principal Investigators

  • Marc de Perrot, MD, FRCSC · UHN - Toronto General Hopsital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-22
Primary Completion
2025-12-31
Completion
2026-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06331455 on ClinicalTrials.gov